Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Conditions: Atypical Carcinoid Tumor; Foregut Neuroendocrine Tumor G1; Hindgut Neuroendocrine Tumor G1; Metastatic Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Midgut Neuroendocrine Tumor G1; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Other: Laboratory Biomarker Analysis; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Drug: Pazopanib Hydrochloride; Other: Placebo Administration; Other: Quality-of-Life Assessment; Procedure: X-Ray Imaging
Sponsors: National Cancer Institute (NCI)
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 15, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments